Momelotinib: First Approval

Overview

Journal Drugs

Specialty Pharmacology

Date 2023 Nov 22

PMID 37989928

Authors

Susan J Keam

Affiliations

Soon will be listed here.

Abstract

Momelotinib (OJJAARA) is an oral Janus kinase 1 and 2 (JAK1/JAK2) and activin A receptor, type I (ACVR1) inhibitor that has been developed for the treatment of myelofibrosis (MF). In September 2023, momelotinib was approved in the USA for the treatment of intermediate or high-risk MF, including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. This article summarizes the milestones in the development of momelotinib leading to this first approval for MF.

Citing Articles

Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma.

Kashyap A, Dai J, Ni X Cancers (Basel). 2025; 17(4).

PMID: 40002165 PMC: 11853177. DOI: 10.3390/cancers17040568.

Neutrophil diversity and function in health and disease.

Zhang F, Xia Y, Su J, Quan F, Zhou H, Li Q Signal Transduct Target Ther. 2024; 9(1):343.

PMID: 39638788 PMC: 11627463. DOI: 10.1038/s41392-024-02049-y.

New and emerging oral therapies for psoriasis.

Yilmaz O, Pinto J, Torres T Drugs Context. 2024; 13.

PMID: 39131603 PMC: 11313207. DOI: 10.7573/dic.2024-5-6.

Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study.

Wang L, Fang L, Shi H, Liu Y, Long C, Guo S Ann Hematol. 2024; 103(9):3605-3613.

PMID: 38907072 DOI: 10.1007/s00277-024-05847-0.

References

Ikeda K, Ueda K . Gaining MOMENTUM against anaemic myelofibrosis. Lancet. 2023; 401(10373):248-249. DOI: 10.1016/S0140-6736(23)00171-X. View

Passamonti F, Mora B . Myelofibrosis. Blood. 2022; 141(16):1954-1970. PMC: 10646775. DOI: 10.1182/blood.2022017423. View

Bassiony S, Harrison C, McLornan D . Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date. Ther Clin Risk Manag. 2020; 16:889-901. PMC: 7524184. DOI: 10.2147/TCRM.S258704. View

Verstovsek S, Chen C, Egyed M, Ellis M, Fox L, Goh Y . MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol. 2021; 17(12):1449-1458. DOI: 10.2217/fon-2020-1048. View

Chifotides H, Bose P, Verstovsek S . Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022; 15(1):7. PMC: 8772195. DOI: 10.1186/s13045-021-01157-4. View

Passamonti F, Harrison C, Mesa R, Kiladjian J, Vannucchi A, Verstovsek S . Anemia in myelofibrosis: Current and emerging treatment options. Crit Rev Oncol Hematol. 2022; 180:103862. DOI: 10.1016/j.critrevonc.2022.103862. View

Asshoff M, Petzer V, Warr M, Haschka D, Tymoszuk P, Demetz E . Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017; 129(13):1823-1830. PMC: 5693322. DOI: 10.1182/blood-2016-09-740092. View

Zheng J, Xin Y, Zhang J, Subramanian R, Murray B, Whitney J . Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development. Drug Metab Dispos. 2018; 46(3):237-247. DOI: 10.1124/dmd.117.078899. View

Oh S, Talpaz M, Gerds A, Gupta V, Verstovsek S, Mesa R . ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020; 4(18):4282-4291. PMC: 7509854. DOI: 10.1182/bloodadvances.2020002662. View

10.

Pardanani A, Laborde R, Lasho T, Finke C, Begna K, Al-Kali A . Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013; 27(6):1322-7. PMC: 3677140. DOI: 10.1038/leu.2013.71. View

11.

Xin Y, Shao L, Maltzman J, Stefanidis D, Hemenway J, Tarnowski T . The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects. Clin Pharmacol Drug Dev. 2017; 7(3):277-286. DOI: 10.1002/cpdd.397. View

12.

Xin Y, Kawashima J, Weng W, Kwan E, Tarnowski T, Silverman J . Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment. J Clin Pharmacol. 2017; 58(4):522-532. DOI: 10.1002/jcph.1050. View

13.

Verstovsek S, Gerds A, Vannucchi A, Al-Ali H, Lavie D, Kuykendall A . Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023; 401(10373):269-280. DOI: 10.1016/S0140-6736(22)02036-0. View

14.

Gerds A, Verstovsek S, Vannucchi A, Al-Ali H, Lavie D, Kuykendall A . Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol. 2023; 10(9):e735-e746. DOI: 10.1016/S2352-3026(23)00174-6. View

15.

Mesa R, Kiladjian J, Catalano J, Devos T, Egyed M, Hellmann A . SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. J Clin Oncol. 2017; 35(34):3844-3850. PMC: 6553796. DOI: 10.1200/JCO.2017.73.4418. View

16.

Harrison C, Vannucchi A, Platzbecker U, Cervantes F, Gupta V, Lavie D . Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017; 5(2):e73-e81. DOI: 10.1016/S2352-3026(17)30237-5. View